ISLAMABAD, Pakistan: The Prime Minister’s Special Assistant on National Health Services Dr. Zafar Mirza has said that Pakistan will soon start manufacturing breakthrough COVID-19 treatment drug Remdesivir under a license from the US Pharmaceutical Company Gilead.
While addressing a news conference in Islamabad on Friday, he said that a Pakistani Pharmaceutical Company has concluded its voluntary licensing agreement with the US Pharmaceutical Company Gilead for the manufacturing and sale of Remdesivir.
The Special Assistant said that Pakistan is among the five Countries with which the US Company has signed a licensing agreement for manufacturing the drug.
Dr. Zafar Mirza said that the production of the medicine can commence as early as eight weeks after the necessary regulatory approvals are obtained.
Furthermore, he said that the development represents an important step forward for Pakistan on the health, economic and diplomacy fronts.
The Special Assistant said that it helps provide our citizens and frontline healthcare workers access to the latest treatment for the pandemic in a fast-track manner.
Dr. Zafar Mirza said that Pakistan will also be able to export the medicine to 127 Countries facing Coronavirus pandemic.
امریکی کمپنی گیلیڈ کی کورونا سے بچاؤ کی دوا کی تیاری کے لیے پاکستان سمیت دنیا کی پانچ مختلف کمپنیوں سےمعاہدے۔یہاں تیار کی جانے والی دوا دنیا کے 127ملکوں کو فراہم کی جائے گی۔دوا کی تیاری 6سے 8 ہفتے کے دوران شروع ہو جا ئے گی۔۔ معاون خصوصی صحت ڈاکٹر ظفر مرزا pic.twitter.com/qcGRz9Sl2Y
— PTV News (@PTVNewsOfficial) May 15, 2020
